MedPath

Effects of Quercetin on plasma total antioxidant capacity, lipid peroxidation, blood pressure, inflammatory markers and disease activity in patients with Rheumatoid Arthritis

Not Applicable
Conditions
Condition 1: Rheumatoid Arthritis. Condition 2: Rheumatoid arthritis.
Seropositive rheumatoid arthritis
Other rheumatoid arthritis
Registration Number
IRCT138807252394N2
Lead Sponsor
Iran Univesity of Medical Sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete
Sex
All
Target Recruitment
50
Inclusion Criteria

Willing to participate in study, Clinical diagnosis of AR (meeting the American college of rheumatology 1987 criteria), Ages between 19 – 70 years , No smoking or addiction , No drug type and dose fluctuation since 1 month prior to the study and during intervention period , Not having severe cardiovascular, hepatic, kidney, gastrointestinal, thyroid, parathyroid diseases, diabetes and inflammation, Not using medications except for AR conventional drugs, Not using antioxidant supplements during last month, No pregnancy or lactation Exclusion criteria: Compliance less than 70%, Disinclination to continue for cooperation, developing illnesses which need particular cures or interfere with intervention such as increasing the disease activity or trauma

Exclusion Criteria

Not provided

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Total antioxidant capacity (TAC). Timepoint: 8 weeks. Method of measurement: colorimetric assay.;Hs-TNF-alpha. Timepoint: 8 weeks. Method of measurement: ELISA.;Hs- CRP. Timepoint: 8 weeks. Method of measurement: ELISA.;Ox-LDL. Timepoint: 8 weeks. Method of measurement: ELISA.;Malondialdehyde. Timepoint: 8 weeks. Method of measurement: chemical colorimetric.;Disease activity score- 28 joints(DAS-28). Timepoint: 8 weeks. Method of measurement: Physical examination.;Morning stiffness. Timepoint: 8 weeks. Method of measurement: question.;Blood pressure. Timepoint: 8 weeks. Method of measurement: sphyngomanometer.
Secondary Outcome Measures
NameTimeMethod
Rheumatoid factor(RF). Timepoint: 8 weeks. Method of measurement: turbidometric assay.;Eritrocyte sedimentation rate(ESR). Timepoint: 8 weeks. Method of measurement: .
© Copyright 2025. All Rights Reserved by MedPath